Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials

Aripiprazole (BMS-337039) for Outpatients With Schizophrenia Completing Aripiprazole Clinical Trials: A Non-Comparative Rollover Protocol

The purpose of this study is to provide aripiprazole to schizophrenic outpatients and Community Treated Patients who are currently receiving aripiprazole therapy on another BMS sponsored clinical trial.

Inclusion Criteria:

• Currently receiving aripiprazole at time of screening
• Men and women ages 18 to 70

Exclusion Criteria:

• All patients previously discontinued from an aripiprazole study for any reason
• Active alcohol or substance abuse
• Patients who represent a significant risk of committing suicide
• Patients with clinically significant abnormal laboratory test results, vital signs or ECG findings